1. Show article details.

    J&J, AbbVie Shares Drop on Potential Drug Competition

    DJ Business News – 1:55 PM ET 02/05/2016

    Shares of AbbVie Inc. (ABBV) and Johnson& Johnson took a hit Friday after U.S. Food and Drug Administration briefing documents hinted a cheaper competitor for the drug companies' blockbuster anti-inflammatory treatments could be headed to market soon. The FDA released the documents a week ahead of Celltrion Inc.' s panel meeting suggesting the Korean pharmaceutical's proposed biosimilar of Johnson& Johnson's Remicade is close enough to be used to treat the same conditions,...

  2. Show article details.

    J&J, AbbVie Shares Drop on Potential Drug Competition

    DJ Business News – 1:37 PM ET 02/05/2016

    Shares of AbbVie Inc. (ABBV) and Johnson& Johnson took a hit Friday after U.S. Food and Drug Administration briefing documents hinted a cheaper competitor for the drug companies' blockbuster anti-inflammatory treatments could be headed to market soon. The FDA released the documents a week ahead of Celltrion Inc.' s panel meeting suggesting the Korean pharmaceutical's proposed biosimilar of Johnson& Johnson's Remicade is close enough to be used to treat the same conditions,...

  3. Johnson & Johnson shares fall 1.8% to lead Dow decliners in early trade

    MarketWatch – 9:34 AM ET 02/05/2016
  4. Show article details.

    FDA staff supports Celltrion's biosimilar Remicade

    Reuters – 9:27 AM ET 02/05/2016

    U.S. Food and Drug Administration staff members on Friday said clinical data from Celltrion Inc's (CONIF) biosimilar form of blockbuster arthritis drug Remicade indicated it is "highly similar" to the branded product in terms of safety, purity and potency. FDA scientists released their supportive findings ahead of a scheduled meeting on Tuesday of an independent medical advisory panel to the agency.

  5. Show article details.

    FDA reviewers support Celltrion's biosimilar Remicade

    Reuters – 7:54 AM ET 02/05/2016

    U.S. Food and Drug Administration staff members on Friday said clinical data from Celltrion Inc's (CONIF) biosimilar form of blockbuster arthritis drug Remicade indicated it is "highly similar" to the branded product in terms of safety, purity and potency.

  6. Show article details.

    Lab criticised as slow to act in fatal French drug trial

    Reuters – 1:33 PM ET 02/04/2016

    An initial inquiry into a clinical drug trial that left one person dead and five others hospitalised in France last month found that the laboratory conducting the tests was slow to react when the first patient fell ill. A full investigation aimed at identifying the exact causes is expected by end-March, French Health Minister Marisol Touraine said on Thursday.

  7. Show article details.

    Pfizer, J&J, Merck evaluating technologies for Zika vaccine

    Reuters – 7:27 AM ET 02/03/2016

    Pfizer Inc (PFE), Johnson and Johnson (JNJ) and Merck & Co Inc (MRK) said they were evaluating their technologies or existing vaccines for their potential to combat Zika, a rapidly spreading mosquito-borne disease linked to birth defects. A number of drug developers and universities are attempting to produce a vaccine for Zika, which the World Health Organization has declared an international health emergency.

  8. Show article details.

    GSK and J&J back $1 billion biotech spin-off from Index Ventures

    Reuters – 5:12 AM ET 02/02/2016

    Index Ventures, an early investor in technology hits like Skype and Dropbox, is spinning off its biotech portfolio into a new $1 billion business, with backing from drug giants GlaxoSmithKline and Johnson & Johnson (JNJ) . The new Medicxi Ventures business will be led by the existing life sciences team from Index Ventures and includes all the current biotech portfolio companies.

  9. Show article details.

    BULLET: US STOCK VIEW: Robert Kavcic of BMO Capital..........

    Market News Intl Fixed Income Bullets – 10:25 AM ET 02/01/2016

    US STOCK VIEW: Robert Kavcic of BMO Capital Markets says recent earnings results show evidence of the negative pull of a stronger US dollar, in varying degrees. "In the consumer space, Amazon's tough quarter was marred by more than $1 bn in foreign exchange losses, while Johnson & Johnson (JNJ) said currency headwinds cut revenue by 7% last year," he says. In terms of US data, trade shaved 0.5% from U.S. real GDP growth in Q4, "as real net exports fell to the lowest level since 2008Q1," Kavcic says. He points out that there are "two basic channels through which profits can be hit by the currency," i.e., "Lower unhedged profits earned abroad, and reduced competiveness in foreign markets." He says both seem now "to be taking a meaningful bite out of earnings growth."

  10. Show article details.

    Cardinal Health Revenue Rises 23%

    DJ Business News – 8:35 AM ET 02/01/2016

    Cardinal Health Inc. (CAH) on Monday reported 23% revenue growth in its latest quarter, driven by its pharmaceutical segment, as the company's top and bottom lines beat analysts' expectations. Cardinal, a drug wholesaler that also makes gloves and surgical apparel, is working to expand its portfolio of medical products as hospitals merge. It provides resources to more than three-quarters of U.S. hospitals.

  11. Show article details.

    Covered Call Alerts For Chesapeake Energy, NRG Energy Inc., Twitter, Johnson & Johnson and JetBlue Released By InvestorsObserver

    PR Newswire – 9:31 AM ET 01/29/2016

    CHICAGO, Jan. 29, 2016  InvestorsObserver issues critical PriceWatch Alerts for CHK, NRG, TWTR, JNJ and JBLU. To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

  12. Show article details.

    BRIEF-EU Medicines Agency approves Bristol-Myers's myeloma treatment

    Reuters – 7:14 AM ET 01/29/2016

    EU Medicines Agency. * EU Medicines Agency recommendations for January 2016. * Recommends approval of Bristol-Myers Squibb's (BMY) myeloma treatment elotuzumab under accelerated assessment. * Recommends approval of Actelion's (ALIOF) selexipag to treat pulmonary arterial hypertension. * CHMP has adopted a final scientific opinion following its review of experimental ebola treatments.

  13. Show article details.

    Bristol-Myers set to lead earnings parade in 2016, beyond

    Reuters – 4:40 PM ET 01/28/2016

    Bristol-Myers Squibb Co (BMY) on Thursday positioned itself as a potential earnings pacesetter in 2016, with a forecast of up to 19 percent growth that eclipses profit gains expected by most other large drugmakers. Bolstered by blistering sales of its Opdivo immuno-oncology drug and its Eliquis blood clot preventer, Bristol-Myers expects earnings this year of $2.30 to $2.40 per share.

  14. Show article details.

    Covered Call Alerts For Chesapeake Energy, NRG Energy Inc., Twitter, Johnson & Johnson and JetBlue Released By InvestorsObserver

    PR Newswire – 9:31 AM ET 01/28/2016

    CHICAGO, Jan. 28, 2016  InvestorsObserver issues critical PriceWatch Alerts for CHK, NRG, TWTR, JNJ and JBLU. To see the high-return covered-call trades uncovered by InvestorsObserver's analysts, read the InvestorsObserver's PriceWatch Alert by selecting the corresponding link.

  15. Show article details.

    Stocks Alerts for Significant Trades Made by CEO, CFO, and Directors of Freeport-McMoRan, Ford Motor, Johnson & Johnson, Procter & Gamble, Oracle Corp, and Exxon Mobil

    PR Newswire – 9:00 AM ET 01/27/2016

    PHOENIX, Jan. 27, 2016 Pennystocksinsiders.com released FREE research reports focusing on the type of insider shareholdings ownership of the following active stocks: Freeport-McMoRan (FCX), Ford Motor (F), Johnson & Johnson (JNJ), Procter & Gamble (PG), Oracle Corp (ORCL), and Exxon Mobil (XOM). Direct ownership means that the shares are actually registered under the insider's name.

  16. Show article details.

    J&J Hit By Strong Dollar

    DJ Business News – 2:47 AM ET 01/27/2016

    By Jonathan D. Rockoff and Chelsey Dulaney. Johnson& Johnson said Tuesday that a strong dollar contributed heavily to a 2.4% drop in fourth-quarter sales to$ 17.8 billion world-wide, but the company expressed optimism that both its underlying business and the global health-care market generally would grow this year. J&J said relatively new drugs such as Xarelto and Imbruvica were driving increased sales in its pharmaceuticals division, while nearly all of the company's...

  17. Show article details.

    J&J profit beats forecasts, helped by lower taxes, cost cuts

    Reuters – 11:01 AM ET 01/26/2016

    - Johnson & Johnson (JNJ) on Tuesday reported higher-than-expected quarterly earnings, helped by lower taxes and cost cuts, and gave a 2016 profit outlook slightly above Wall Street's. Shares of the diversified healthcare company rose 2.9 percent to $99.20 in morning trading as investors shrugged off fourth-quarter sales and a 2016 revenue outlook that were both below analysts' estimates.

  18. Show article details.

    BRIEF-J&J says valuations of potential acquisitions in 2015 were inflated

    Reuters – 10:15 AM ET 01/26/2016

    Johnson & Johnson CEO, in conference call: * Says company will remain very active in mergers and acquisitions. * Says valuations of potential acquisition targets in 2015 were overly high. *

  19. Show article details.

    Biosimilar drugs get boost as UK cost agency backs their use

    Reuters – 9:48 AM ET 01/26/2016

    Cheaper "biosimilar" copies of expensive biotech drugs received a boost in Britain on Tuesday when the country's health cost-effectiveness agency NICE said patients needing such medicines "should be started with the least expensive drug".

  20. Show article details.

    Strong U.S. Drug Sales at J&J Undercut by Currency Exchange

    DJ Business News – 7:55 AM ET 01/26/2016

    Johnson& Johnson said Tuesday that a strong dollar contributed heavily to a 2.4% drop in fourth- quarter sales to $17.8 billion world-wide, but the company expressed optimism that both its underlying business and the global health-care market generally would grow this year. J&J said relatively new drugs such as Xarelto and Imbruvica were driving increased sales in its pharmaceuticals division, while nearly all of the company's recalled consumer health-products like...

Page:

Today's and Upcoming Events

  • Feb
    19

    JNJ ex-Dividend for $0.75 on 2/19/2016

    • Announce Date: 1/4/2016
    • Record Date: 2/23/2016
    • Pay Date: 3/8/2016
  • Apr
    12

    JNJ to announce Q1 earnings Before Market (Unconfirmed)

Past Events (last 90 days)

  • Jan
    26

    JNJ Earnings Conference Call at 8:30 AM Listen

Data provided by Wall Street Horizon, Inc. © 2016

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.